{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:11:16Z","timestamp":1778253076795,"version":"3.51.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s HORIZON","award":["MISS-2022-CANCER-01-03"],"award-info":[{"award-number":["MISS-2022-CANCER-01-03"]}]},{"name":"European Union\u2019s HORIZON","award":["101103655"],"award-info":[{"award-number":["101103655"]}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["K135757"],"award-info":[{"award-number":["K135757"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["TKP2021-EGA-24"],"award-info":[{"award-number":["TKP2021-EGA-24"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>AbstractAbstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glioblastoma is considered one of the deadliest malignant solid tumors. The disease severity and the treatment intensity place a significant burden on patients, their family and caregivers, and the health systems. This study aimed to review the methodological aspects and quality of economic evaluations and health economic models in glioblastoma with a special focus on Europe and North America.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A search was performed covering Medline (via PubMed), Embase, Scopus, Cochrane Library, and PROSPERO. Gray literature search and snowball sampling were also conducted. Studies were eligible if they included glioblastoma patients, contained data on economic evaluations, and were in our geographical focus. The protocol was registered in PROSPERO (ID: CRD42023488181).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The review of 4052 records resulted in 19 peer-reviewed articles, 1 health technology assessment agency document, 2 conference posters, and 1 thesis. Most studies investigated pharmaceuticals in combination with radiotherapy (n = 7). Five studies focused on tumor-treating fields in combination with maintenance temozolomide. Most studies investigated newly diagnosed patients (n = 18). Economic modeling was used in 15 cases; the majority used the \"traditional\" 3-state Markov cohort or partitioned-survival modeling approach (health states: progression-free, progressed, dead). Input data, particularly for utilities, were outdated in many cases. We identified only 2 studies with societal perspective, and these had limited scope.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our review identified gaps in the literature related to the economic evaluations on relapsed glioblastoma patients and to comprehensive assessments using a societal perspective. We also concluded that there is a lack of relevant, high-quality, and up-to-date utility data for glioblastoma in the studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/nop\/npaf113","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T12:51:12Z","timestamp":1761655872000},"page":"238-251","source":"Crossref","is-referenced-by-count":0,"title":["Methodological aspects of economic evaluations and health economic models in glioblastoma: A systematic literature review"],"prefix":"10.1093","volume":"13","author":[{"given":"Erika","family":"Orsz\u00e1gh","sequence":"first","affiliation":[{"name":"Syreon Research Institute , Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"J\u00f3zwiak-Hagym\u00e1sy","sequence":"additional","affiliation":[{"name":"Syreon Research Institute , Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"D\u00f3czi","sequence":"additional","affiliation":[{"name":"Syreon Research Institute , Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00f3ra","family":"Mezei","sequence":"additional","affiliation":[{"name":"Syreon Research Institute , Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertalan","family":"N\u00e9meth","sequence":"additional","affiliation":[{"name":"Syreon Research Institute , Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9di","family":"Varga","sequence":"additional","affiliation":[{"name":"Syreon Research Institute , Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6966-1622","authenticated-orcid":false,"given":"Attila","family":"Tordai","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Semmelweis University , Budapest (A.T.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7288-8975","authenticated-orcid":false,"given":"Tomas","family":"Kazda","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Masaryk Memorial Cancer Institute , Brno (T.K.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Gorlia","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer (EORTC) Headquarters , Brussels (T.G., C.Q.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Quoilin","sequence":"additional","affiliation":[{"name":"European Organisation for Research and Treatment of Cancer (EORTC) Headquarters , Brussels (T.G., C.Q.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Division of Oncology, Medical University of Vienna , Vienna (M.P.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Minniti","sequence":"additional","affiliation":[{"name":"Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome , Rome (G.M.)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcell","family":"Csan\u00e1di","sequence":"additional","affiliation":[{"name":"Syreon Research Institute , Budapest (E.O., J.J.-H., T.D., D.M., B.N., H.V., M.C.)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"2026050810214516500_npaf113-B1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1200\/JCO.2017.73.0119","article-title":"Adult glioblastoma","volume":"35","author":"Alexander","year":"2017","journal-title":"J Clin Oncol."},{"key":"2026050810214516500_npaf113-B2","author":"Dietrich"},{"key":"2026050810214516500_npaf113-B3","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jamaoncol.2022.2844","article-title":"World Health Organization 2021 classification of central nervous system tumors and implications for therapy for adult-type gliomas: a review","volume":"8","author":"Berger","year":"2022","journal-title":"JAMA Oncol."},{"key":"2026050810214516500_npaf113-B4","first-page":"669","article-title":"An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825","volume":"19","author":"Gittleman","year":"2017","journal-title":"Neuro Oncol"},{"key":"2026050810214516500_npaf113-B5","author":"Batchelor"},{"key":"2026050810214516500_npaf113-B6","author":"Batchelor"},{"key":"2026050810214516500_npaf113-B7","author":"Shih"},{"key":"2026050810214516500_npaf113-B8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"key":"2026050810214516500_npaf113-B9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol."},{"key":"2026050810214516500_npaf113-B10","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"2026050810214516500_npaf113-B11","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.3390\/cancers14153669","article-title":"Tumor-treating fields in glioblastomas: past, present, and future","volume":"14","author":"Guo","year":"2022","journal-title":"Cancers (Basel"},{"key":"2026050810214516500_npaf113-B12","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/13696998.2021.1964775","article-title":"Economic implications of the modern treatment paradigm of glioblastoma: an analysis of global cost estimates and their utility for cost assessment","volume":"24","author":"Goel","year":"2021","journal-title":"J Med Econ"},{"key":"2026050810214516500_npaf113-B13","first-page":"153","article-title":"Current challenges in health economic modeling of cancer therapies: a research inquiry","volume":"7","author":"Miller","year":"2014","journal-title":"Am Health Drug Benefits."},{"key":"2026050810214516500_npaf113-B14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40258-019-00513-3","article-title":"A review of recent decision-analytic models used to evaluate the economic value of cancer treatments","volume":"17","author":"Bullement","year":"2019","journal-title":"Appl Health Econ Health Policy."},{"key":"2026050810214516500_npaf113-B15","doi-asserted-by":"crossref","first-page":"104345","DOI":"10.1016\/j.critrevonc.2024.104345","article-title":"Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: a systematic review","volume":"197","author":"Roets","year":"2024","journal-title":"Crit Rev Oncol Hematol."},{"key":"2026050810214516500_npaf113-B16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40259-023-00583-9","article-title":"Systematic literature review of economic evaluations of treatment alternatives in chronic lymphocytic leukemia","volume":"37","author":"Lorenzovici","year":"2023","journal-title":"BioDrugs."},{"key":"2026050810214516500_npaf113-B17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40273-014-0198-y","article-title":"A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments","volume":"32","author":"Messali","year":"2014","journal-title":"Pharmacoeconomics."},{"key":"2026050810214516500_npaf113-B18","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026050810214516500_npaf113-B19","author":"Orsz\u00e1gh"},{"key":"2026050810214516500_npaf113-B20"},{"key":"2026050810214516500_npaf113-B21","author":"Haddaway"},{"key":"2026050810214516500_npaf113-B22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","article-title":"Risk of bias in model-based economic evaluations: the ECOBIAS checklist","volume":"16","author":"Adarkwah","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res."},{"key":"2026050810214516500_npaf113-B23","doi-asserted-by":"crossref","first-page":"743979","DOI":"10.3389\/fphar.2021.743979","article-title":"Cost-effectiveness of short-course radiation plus temozolomide for the treatment of newly diagnosed glioblastoma among elderly patients in China and the United States","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026050810214516500_npaf113-B24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10198-020-01239-z","article-title":"A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme","volume":"22","author":"Connock","year":"2021","journal-title":"European J Health Econ."},{"key":"2026050810214516500_npaf113-B25","author":"Fischer","year":"2016"},{"key":"2026050810214516500_npaf113-B26","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.2014.59.7245","article-title":"Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme","volume":"33","author":"Kovic","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026050810214516500_npaf113-B27","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/neuonc\/not096","article-title":"The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States","volume":"15","author":"Messali","year":"2013","journal-title":"Neuro-Oncology."},{"key":"2026050810214516500_npaf113-B28","author":"NICE","year":"2007"},{"key":"2026050810214516500_npaf113-B29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11060-018-2804-x","article-title":"Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany","volume":"138","author":"Waschke","year":"2018","journal-title":"J Neurooncol"},{"key":"2026050810214516500_npaf113-B30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy\u2013temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med."},{"key":"2026050810214516500_npaf113-B31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med."},{"key":"2026050810214516500_npaf113-B32","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/neuonc\/now102","article-title":"The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma","volume":"18","author":"Bernard-Arnoux","year":"2016","journal-title":"Neuro Oncol."},{"key":"2026050810214516500_npaf113-B33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11060-019-03197-w","article-title":"Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model","volume":"143","author":"Connock","year":"2019","journal-title":"J Neuro-Oncol."},{"key":"2026050810214516500_npaf113-B34","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jval.2023.09.629","article-title":"EE363 cost-effectiveness analysis of adding tumor treating fields therapy to temozolomide versus temozolomide only in patients with glioblastoma in France","volume":"26","author":"Nino de Rivera Guzman","year":"2023","journal-title":"Value Health"},{"key":"2026050810214516500_npaf113-B35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1080\/13696998.2019.1614933","article-title":"Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study","volume":"22","author":"Guzauskas","year":"2019","journal-title":"J Med Econ."},{"key":"2026050810214516500_npaf113-B36","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA."},{"key":"2026050810214516500_npaf113-B37","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"2026050810214516500_npaf113-B38","doi-asserted-by":"crossref","first-page":"A638","DOI":"10.1016\/j.jval.2014.08.2298","article-title":"Cost-effectiveness analysis of bevacizumab, fotemustine and extended-dose temozolomide in patients with recurrent glioblastoma in Spain","volume":"17","author":"Garcia Lopez","year":"2014","journal-title":"Value Health."},{"key":"2026050810214516500_npaf113-B39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00019053-200523080-00006","article-title":"Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme","volume":"23","author":"Martikainen","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"2026050810214516500_npaf113-B40","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fonc.2019.00814","article-title":"Cost-effectiveness of [18F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma","volume":"9","author":"Baguet","year":"2019","journal-title":"Front Oncol"},{"key":"2026050810214516500_npaf113-B41","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3171\/2019.3.JNS182629","article-title":"Insurance type impacts the economic burden and survival of patients with newly diagnosed glioblastoma","volume":"133","author":"Chandra","year":"2020","journal-title":"J Neurosurg."},{"key":"2026050810214516500_npaf113-B42","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta11450","article-title":"The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation","volume":"11","author":"Garside","year":"2007","journal-title":"Health Technol Assess."},{"key":"2026050810214516500_npaf113-B43","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1634\/theoncologist.2018-0093","article-title":"Expenditures on oncology drugs and cancer mortality-to-incidence ratio in Central and Eastern Europe","volume":"24","author":"Vrdoljak","year":"2019","journal-title":"Oncologist"},{"key":"2026050810214516500_npaf113-B44","doi-asserted-by":"crossref","first-page":"17588359241264727","DOI":"10.1177\/17588359241264727","article-title":"Cost-effectiveness analysis of 11 pharmacotherapies for recurrent glioblastoma in the USA and China","volume":"16","author":"Xu","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"2026050810214516500_npaf113-B45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s13063-024-08213-7","article-title":"Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study","volume":"25","author":"Preusser","year":"2024","journal-title":"Trials."},{"key":"2026050810214516500_npaf113-B46","doi-asserted-by":"crossref","first-page":"1191480","DOI":"10.3389\/fphar.2023.1191480","article-title":"Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npaf113\/65044163\/npaf113.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/2\/238\/65044163\/npaf113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/2\/238\/65044163\/npaf113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T14:21:55Z","timestamp":1778250115000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/13\/2\/238\/8307062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npaf113","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,10,30]]}}}